If you’re starting a GLP-1 medication like semaglutide or tirzepatide, you’ve probably asked:
When will I see results?
What should I expect in month one? Month three? Month six?
While every body responds differently, there are some common patterns in how weight loss, appetite, and side effects evolve over time. In this blog, we break it down by stage—so you know what’s normal, what’s worth celebrating, and when to reach out for support.
What’s happening:
This is the introductory phase. Most people start at a low dose (e.g., 0.25 mg for semaglutide) to help minimize side effects and allow the body to adjust.
What to expect:
Pro tip: Focus on hydration, light meals, and consistency with dosing. Weight loss may feel slow, but your body is making major internal changes.at room temp for a few weeks (check your specific prescription), but if unopened, they must stay cold.
What’s happening:
Doses are typically increased gradually by this point, and your body is more adapted to the medication. This is when many people really start to notice progress.
What to expect:
Pro tip: This is a great time to add movement and increase protein to preserve muscle while burning fat. It also helps reduce plateaus later.
What’s happening:
By now, the medication has fully reshaped your hunger hormones, eating habits, and metabolism. You’re likely well into your weight loss journey—or entering maintenance mode.
What to expect:
Pro tip: Don’t panic if progress slows. This is a natural phase. Focus on consistency, strength, and habits—not just the number on the scale.
GLP-1s are powerful tools—but real change takes time. Expect shifts in appetite early on, steady fat loss by month three, and deep, lasting transformation around month six.
The more patient and prepared you are, the more sustainable your results will be.
Curious which GLP-1 program is right for you? Click here to compare trusted telehealth providers.
The cast of Wicked: For Good dazzled in early promotional photos — but not for the reasons anyone expected. Instead of discussions about acting, choreography, or cinematic magic, social media conversations centered on something far more concerning: When Thin Isn’t a Win.
For years, GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have been known for their powerful effects on appetite control, blood sugar regulation, and weight loss. But new research reveals a surprising frontier: GLP-1 drugs may also influence addiction pathways, including those related to smoking, tobacco use, nicotine dependence, alcohol misuse, and opioid addiction.
For decades, opioid addiction has ravaged lives and communities. The combination of dependence, relapse risk, and overdose deaths has made finding new, effective treatments a public health priority. Emerging research now suggests that GLP-1 receptor agonists — drugs originally developed to treat type 2 diabetes and obesity — may play a surprising role in reducing opioid cravings and substance abuse behaviors. GLP-1 & Opioid Addiction.
